An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

This study has been completed.
Sponsor:
Information provided by:
Robin, Alan L., M.D.
ClinicalTrials.gov Identifier:
NCT00329095
First received: May 19, 2006
Last updated: May 22, 2006
Last verified: May 2006
  Purpose

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.


Condition Intervention Phase
Glaucoma
Ocular Hypertension
Drug: travoprost, latanoprost, or bimatoprost
Drug: Additional ocular hypotensive medication
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures

Resource links provided by NLM:


Further study details as provided by Robin, Alan L., M.D.:

Primary Outcome Measures:
  • Compliance.

Estimated Enrollment: 60
Study Start Date: December 2005
Estimated Study Completion Date: April 2006
Detailed Description:

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Currently using one or two topical ocular hypotensive medications

Exclusion Criteria:

  • Hypersensitivity to any component of medication
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00329095

Sponsors and Collaborators
Robin, Alan L., M.D.
Investigators
Principal Investigator: Alan L. Robin, MD Alan L. Robin, M.D.
  More Information

No publications provided by Robin, Alan L., M.D.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00329095     History of Changes
Other Study ID Numbers: GMED-01
Study First Received: May 19, 2006
Last Updated: May 22, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Robin, Alan L., M.D.:
Glaucoma
Compliance

Additional relevant MeSH terms:
Glaucoma
Hypertension
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Latanoprost
Travoprost
Bimatoprost
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 15, 2014